Functional characterization of the protease of human endogenous retrovirus, K10: Can it complement HIV-1 protease?

被引:51
作者
Towler, EM
Gulnik, SV
Bhat, TN
Xie, D
Gustschina, E
Sumpter, TR
Robertson, N
Jones, C
Sauter, M
Mueller-Lantzsch, N
Debouck, C
Erickson, JW
机构
[1] NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Prot Chem Lab, Frederick, MD 21702 USA
[2] NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Struct Biochem Program, Frederick, MD 21702 USA
[3] SmithKline Beecham Pharmaceut, Dept Mol Genet, King Of Prussia, PA 19406 USA
[4] Univ Saarlandes Kliniken, Inst Med Mikrobiol & Hyg, Abt Virol, D-66421 Homburg, Germany
关键词
D O I
10.1021/bi9818927
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
TO investigate the biochemical properties of the protease encoded by the human endogenous retrovirus, K10 (HERV-K), 213 amino acids of the 3'-end of the HERV-K protease (PR) open reading frame were expressed in Escherichia coli. Autocatalytic cleavage of the expressed polypeptide resulted in an 18.2 kDa protein which was shown to be proteolytically active against a fluorogenic peptide used as a substrate for HIV-1 protease. On the basis of sequence homology and molecular modeling, the 106 N-terminal amino acids of HERV-K PR were predicted to comprise a retroviral protease core domain. An 11.6 kDa protein corresponding to this region was expressed and shown to be a fully functional enzyme. The 11.6 kDa domain of HERV-K PR is unusually stable over a wide pH range, exhibits optimal catalytic activity between pH 4.0 and 5.0, and exists as a dimer at pH 7.0 with a K-d of 50 mu M. Like HIV-1 PR, the HERV-K PR core domain is activated by high salt concentrations and processes HIV-1 matrix-capsid polyprotein at the authentic HIV-1 PR recognition site. However, both the 18.2 and 11.6 kDa forms of HERV-K PR were highly resistant to a number of clinically useful HIV-1 PR inhibitors, including ritonavir, indinavir, and saquinavir. This raises the possibility that HERV-K PR may complement HIV-1 PR during infection, and could have implications for protease inhibitor therapy and drug resistance.
引用
收藏
页码:17137 / 17144
页数:8
相关论文
共 26 条
[1]   STRUCTURE OF HIV-1 PROTEASE WITH KNI-272, A TIGHT-BINDING TRANSITION-STATE ANALOG CONTAINING ALLOPHENYLNORSTATINE [J].
BALDWIN, ET ;
BHAT, TN ;
GULNIK, S ;
LIU, BS ;
TOPOL, IA ;
KISO, Y ;
MIMOTO, T ;
MITSUYA, H ;
ERICKSON, JW .
STRUCTURE, 1995, 3 (06) :581-590
[2]   GenBank [J].
Benson, Dennis A. ;
Karsch-Mizrachi, Ilene ;
Lipman, David J. ;
Ostell, James ;
Sayers, Eric W. .
NUCLEIC ACIDS RESEARCH, 2011, 39 :D32-D37
[3]  
Coffin JM, 1997, RETROVIRUSES
[4]   DISSOCIATION AND ASSOCIATION OF THE HIV-1 PROTEASE DIMER SUBUNITS - EQUILIBRIA AND RATES [J].
DARKE, PL ;
JORDAN, SP ;
HALL, DL ;
ZUGAY, JA ;
SHAFER, JA ;
KUO, LC .
BIOCHEMISTRY, 1994, 33 (01) :98-105
[5]   THE NOT-SO-GREAT ESCAPE [J].
ERICKSON, JW .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (07) :523-529
[6]   KINETIC CHARACTERIZATION AND CROSS-RESISTANCE PATTERNS OF HIV-1 PROTEASE MUTANTS SELECTED UNDER DRUG PRESSURE [J].
GULNIK, SV ;
SUVOROV, LI ;
LIU, BS ;
YU, B ;
ANDERSON, B ;
MITSUYA, H ;
ERICKSON, JW .
BIOCHEMISTRY, 1995, 34 (29) :9282-9287
[7]   CLONING, BACTERIAL EXPRESSION, AND CHARACTERIZATION OF THE MASON-PFIZER MONKEY VIRUS PROTEINASE [J].
HRUSKOVAHEIDINGSFELDOVA, O ;
ANDREANSKY, M ;
FABRY, M ;
BLAHA, I ;
STROP, P ;
HUNTER, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (25) :15053-15058
[8]  
JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301
[9]   INVITRO ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ACTIVITIES OF TRANSITION-STATE MIMETIC HIV PROTEASE INHIBITORS CONTAINING ALLOPHENYLNORSTATINE [J].
KAGEYAMA, S ;
MIMOTO, T ;
MURAKAWA, Y ;
NOMIZU, M ;
FORD, H ;
SHIRASAKA, T ;
GULNIK, S ;
ERICKSON, J ;
TAKADA, K ;
HAYASHI, H ;
BRODER, S ;
KISO, Y ;
MITSUYA, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :810-817
[10]   The viruses in all of us: Characteristics and biological significance of human endogenous retrovirus sequences [J].
Lower, R ;
Lower, J ;
Kurth, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (11) :5177-5184